Research programme: bispecific antibodies - Innovent Biologics

Drug Profile

Research programme: bispecific antibodies - Innovent Biologics

Alternative Names: IBI 322

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innovent Biologics
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 Jul 2018 Preclinical trials in Cancer in China (Parenteral) (Innovent Biologics pipeline, July 2018)
  • 06 Jun 2016 Innovent Biologics in-licenses EpimAb's FIT-Ig® technology to develop and further license bispecific antibodies
  • 06 Jun 2016 Early research in Undefined indication in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top